scholarly journals Simian immunodeficiency virus induces expression of class II major histocompatibility complex structures on infected target cells in vitro.

1987 ◽  
Vol 61 (5) ◽  
pp. 1421-1426 ◽  
Author(s):  
M Kannagi ◽  
M Kiyotaki ◽  
N W King ◽  
C I Lord ◽  
N L Letvin
1999 ◽  
Vol 73 (5) ◽  
pp. 3692-3701 ◽  
Author(s):  
Cheng Yin ◽  
Mary S. Wu ◽  
C. David Pauza ◽  
Maria S. Salvato

ABSTRACT Before the development of virus-specific immune responses, peripheral blood mononuclear cells (PBMC) from uninfected rhesus monkeys and human beings have the capacity to lyse target cells expressing simian immunodeficiency virus (SIV) or human immunodeficiency virus-1 (HIV) envelope (gp130 and gp120) antigens. Lysis by naive effector cells does not require major histocompatibility complex (MHC)-restricted antigen presentation, is equally effective for allogeneic and xenogeneic targets, and is designated MHC-unrestricted (UR) lysis. UR lysis is not sensitive to EGTA and does not require de novo RNA or protein synthesis. Several kinds of envelope-expressing targets, including cells that poorly express MHC class I antigens, can be lysed. CD4+ effectors are responsible for most of the lytic activity. High lysis is correlated with high expression of HIV or SIV envelope, specifically, the central one-third of the gp130 molecule, and lysis is completely inhibited by a monoclonal antibody against envelope. Our work extends observations of human lymphocytes expressing HIV gp120 to the SIV/rhesus monkey model for AIDS. Additionally, we address the relevance of UR lysis in vivo. A survey of PBMC from 56 uninfected rhesus monkeys indicates that 59% of the individuals had peak UR lytic activity above 15% specific lysis. Eleven of these monkeys were subsequently infected with SIV. Animals with UR lytic activity above 15% specific lysis were predisposed to more rapid disease progression than animals with low UR lytic activity, suggesting a strong correlation between this form of innate immunity and disease progression to AIDS.


2018 ◽  
Vol 34 ◽  
pp. 35-38
Author(s):  
Cyrielle Hou ◽  
Yasmine Baba-Amer ◽  
Maximilien Bencze ◽  
Frédéric Relaix ◽  
François Jérôme Authier

Les myopathies inflammatoires et dysimmunitaires (DIMs) touchent 14/100 000 personnes dans le monde. Ces pathologies sont classées par des critères immunopathologiques en quatre groupes : (1) polymyosites (PM)/ myosites à inclusions (IBM), (2) dermatomyosites, (3) myopathies nécrosantes auto-immunes et (4) myosites de chevauchement comprenant le syndrome anti-synthétase (ASS). Les ASS et PM/IBM sont caractérisées par la présence d’infiltrats inflammatoires mononucléés. Récemment, nous avons mis en évidence une expression myocytaire du complexe majeur d’histocompatibilité de type 2 (CMH2) dans les muscles de patients atteints d’ASS et d’IBM. L’expression du CMH2 est connue pour être induite par l’interféron-gamma (IFNγ) dans les cellules myogéniques. Or, les lymphocytes T CD8 (LTCD8), cellules productrices d’IFNγ sont retrouvés à proximité des fibres musculaires CMH2 positives. Cette cytokine inhibe la différenciation musculaire in vitro par l’interaction CIITA-myogénine (CIITA : major histocompatibility complex class II transactivator). Les mécanismes impliquant une toxicité musculaire médiée par les lymphocytes dans les DIMs restent inconnus. Les objectifs de ce projet sont dans un premier temps de caractériser les effets de l’IFNγ sur la biologie des cellules musculaires par des approches morphologiques, moléculaires et cellulaires. Puis, d’identifier le rôle de l’IFNγ dans ces myopathies et son impact au cours de la régénération musculaire. Des études préliminaires in vitro ont été réalisées sur des myoblastes humains et murins exposés ou non à l’IFNγ. Nos résultats devraient permettre d’obtenir de meilleures connaissances sur la physiopathologie des DIMs et d’identifier de potentielles nouvelles cibles thérapeutiques.


2004 ◽  
Vol 78 (23) ◽  
pp. 13335-13344 ◽  
Author(s):  
Tomek Swigut ◽  
Louis Alexander ◽  
Jennifer Morgan ◽  
Jeff Lifson ◽  
Keith G. Mansfield ◽  
...  

ABSTRACT Functional activities that have been ascribed to the nef gene product of simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV) include CD4 downregulation, major histocompatibility complex (MHC) class I downregulation, downregulation of other plasma membrane proteins, and lymphocyte activation. Monkeys were infected experimentally with SIV containing difficult-to-revert mutations in nef that selectively eliminated MHC downregulation but not these other activities. Monkeys infected with these mutant forms of SIV exhibited higher levels of CD8+ T-cell responses 4 to 16 weeks postinfection than seen in monkeys infected with the parental wild-type virus. Furthermore, unusual compensatory mutations appeared by 16 to 32 weeks postinfection which restored some or all of the MHC-downregulating activity. These results indicate that nef does serve to limit the virus-specific CD8 cellular response of the host and that the ability to downregulate MHC class I contributes importantly to the totality of nef function.


2002 ◽  
Vol 76 (13) ◽  
pp. 6425-6434 ◽  
Author(s):  
Parul G. Patel ◽  
Monica T. Yu Kimata ◽  
Julia E. Biggins ◽  
Joelle M. Wilson ◽  
Jason T. Kimata

ABSTRACT The replicative, cytopathic, and antigenic properties of simian immunodeficiency virus (SIV) variants influence its replication efficiency in vivo. To further define the viral properties and determinants that may be important for high-level replication in vivo and progression to AIDS, we compared a minimally pathogenic SIVmne molecular clone with two highly pathogenic variants cloned from late stages of infection. Both variants had evolved greater infectivity than the parental clone due to mutations in nef. Interestingly, a pol determinant in one of the highly pathogenic variants also contributed to its increased infectivity. Furthermore, because replication in vivo may also be influenced by the ability of a virus to evade the cellular immune response of the host, we examined whether the variants were more capable of downregulating surface expression of class I major histocompatibility complex (MHC). Decreased MHC class I expression was not observed in cells infected with any of the viruses. Furthermore, the Nef proteins of the highly pathogenic variants only slightly reduced surface MHC class I expression in transfected cells, although they efficiently downregulated CD4. Together, these data demonstrate that mutations which can enhance viral infectivity, as well as CD4 downregulation, may be important for efficient replication of SIV in the host. However, Nef-mediated reduction of MHC class I expression does not appear to be critical for the increased in vivo replicative ability of highly pathogenic late variants.


2000 ◽  
Vol 20 (22) ◽  
pp. 8489-8498 ◽  
Author(s):  
Charalambos Spilianakis ◽  
Joseph Papamatheakis ◽  
Androniki Kretsovali

ABSTRACT The class II transactivator (CIITA), the master regulator of the tissue-specific and interferon gamma-inducible expression of major histocompatibility complex class II genes, synergizes with the histone acetylase coactivator CBP to activate gene transcription. Here we demonstrate that in addition to CBP, PCAF binds to CIITA both in vivo and in vitro and enhances CIITA-dependent transcriptional activation of class II promoters. Accordingly, E1A mutants defective for PCAF or CBP interaction show reduced ability in suppressing CIITA activity. Interestingly, CBP and PCAF acetylate CIITA at lysine residues within a nuclear localization signal. We show that CIITA is shuttling between the nucleus and cytoplasm. The shuttling behavior and activity of the protein are regulated by acetylation: overexpression of PCAF or inhibition of cellular deacetylases by trichostatin A increases the nuclear accumulation of CIITA in a manner determined by the presence of the acetylation target lysines. Furthermore, mutagenesis of the acetylated residues reduces the transactivation ability of CIITA. These results support a novel function for acetylation, i.e., to regulate gene expression by stimulating the nuclear accumulation of an activator.


2001 ◽  
Vol 75 (2) ◽  
pp. 738-749 ◽  
Author(s):  
Todd M. Allen ◽  
Bianca R. Mothé ◽  
John Sidney ◽  
Peicheng Jing ◽  
John L. Dzuris ◽  
...  

ABSTRACT It is becoming increasingly clear that any human immunodeficiency virus (HIV) vaccine should induce a strong CD8+ response. Additional desirable elements are multispecificity and a focus on conserved epitopes. The use of multiple conserved epitopes arranged in an artificial gene (or EpiGene) is a potential means to achieve these goals. To test this concept in a relevant disease model we sought to identify multiple simian immunodeficiency virus (SIV)-derived CD8+ epitopes bound by a single nonhuman primate major histocompatibility complex (MHC) class I molecule. We had previously identified the peptide binding motif of Mamu-A*012, a common rhesus macaque MHC class I molecule that presents the immunodominant SIV gag-derived cytotoxic T lymphocyte (CTL) epitope Gag_CM9 (CTPYDINQM). Herein, we scanned SIV proteins for the presence of Mamu-A*01 motifs. The binding capacity of 221 motif-positive peptides was determined using purified Mamu-A*01 molecules. Thirty-seven peptides bound with apparentKd values of 500 nM or lower, with 21 peptides binding better than the Gag_CM9 peptide. Peripheral blood mononuclear cells from SIV-infected Mamu-A*01+ macaques recognized 14 of these peptides in ELISPOT, CTL, or tetramer analyses. This study reveals an unprecedented complexity and diversity of anti-SIV CTL responses. Furthermore, it represents an important step toward the design of a multiepitope vaccine for SIV and HIV.


Sign in / Sign up

Export Citation Format

Share Document